Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00783783 · ClinicalTrials.gov registry record
CYP2D6 Pharmacogenetics in Risperidone-Treated Children
A clinical trial of Neurodevelopmental Disorders and Psychiatric Disorders, sponsored by Children's Hospital Medical Center, Cincinnati.
- Completed
- Registry status
- 47
- Enrollment target
- 1
- Study location
NCT00783783: Completed study of Neurodevelopmental Disorders and Psychiatric Disorders, sponsored by Children's Hospital Medical Center, Cincinnati.
NCT00783783 is a study of Neurodevelopmental Disorders and Psychiatric Disorders that has completed, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 47 participants, below the 580-participant average among 27 other Neurodevelopmental Disorders trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00783783, a study of Neurodevelopmental Disorders and Psychiatric Disorders, has completed, sponsored by Children's Hospital Medical Center, Cincinnati.
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
Risperidone is an important medication used to treat children with psychiatric illnesses or neurodevelopmental disorders, such as autism. Despite excellent symptom control, the potential for side effects is worrisome. Treating these disorders is difficult because not everyone responds the same way to the same risperidone dose. One reason for this is genetic differences in how people break down the drug. Understanding these differences will help clinicians choose a dose and better predict the response so patients will be treated successfully with a lower risk for side effects. This study will research these genetic differences in children with psychiatric or neurodevelopmental disorders. Hypothesis: The inter-patient variability in risperidone pharmacokinetics and exposure, adverse events, and clinical response in patients with psychiatric or neurodevelopmental disorders is associated with identifiable pharmacogenetic factors, such as CYP2D6 single nucleotide polymorphisms (SNPs).
Conditions Studied
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2008-11 |
| Est. Completion | 2011-06 |
What the finished NCT00783783 record still lists
NCT00783783 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 580-participant average among 27 other Neurodevelopmental Disorders trials with a reported enrollment target (92% lower).
The record links to 2 conditions, with Neurodevelopmental Disorders appearing as the primary indexed condition, and to 0 interventions.
NCT00783783 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00783783 about?
NCT00783783 is a clinical study titled "CYP2D6 Pharmacogenetics in Risperidone-Treated Children". Risperidone is an important medication used to treat children with psychiatric illnesses or neurodevelopmental disorders, such as autism. Despite excellent symptom control, the potential for side effects is worrisome. Treating these disorders is difficult because not everyone responds the same way t...
What is the current status of trial NCT00783783?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2008-11. Estimated completion is 2011-06.
What conditions does trial NCT00783783 study?
This clinical trial studies the following conditions: Neurodevelopmental Disorders, Psychiatric Disorders.
Who is sponsoring clinical trial NCT00783783?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00783783 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neurodevelopmental Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00783783's enrollment target sits among peer trials
47 24th of 27 higher than 4 of 27 other Neurodevelopmental Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Neurodevelopmental Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Physical Activity and Community EmPOWERment Project
RECRUITING · NA
-
SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
RECRUITING
-
Rett Syndrome Registry
RECRUITING
-
Motor-voice Assessment in Infants (MAMI)
RECRUITING
-
Natural History Study of GEMIN-5 Related Neurodevelopmental Disorder
RECRUITING
-
Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia